我的购物车

GMP Human Thrombopoietin ProteinDMF

  • PG version THN-H5216 is now available for seamless transition.
用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

  • 优势特色(Features)

    1. Designed under ISO 9001:2015 and ISO 13485:2016
    2. Manufactured and QC tested under a GMP compliance factory
    3. FDA DMF filed
    4. Animal-Free materials
    5. Beta-lactam materials free
    6. Batch-to-batch consistency
    7. Stringent quality control tests
  • 表达区间及表达系统(Source)

    GMP Human Thrombopoietin Protein (GMP-THNH25) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Gly 353 (Accession # P40225-1).

    Predicted N-terminus: Ser 22

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    Thrombopoietin Structure

    This protein carries no "tag".

    The protein has a calculated MW of 35.5 kDa. The protein migrates as 75 kDa±5 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 偶联(Conjugate)

    Unconjugated

  • 内毒素(Endotoxin)

    Less than 10 EU/mg by the LAL method.

  • 宿主蛋白残留(Host Cell Protein)

    0.5 ng/µg of protein tested by ELISA.

  • 宿主核酸残留(Host Cell DNA)

    0.02 ng/μg of protein tested by qPCR.

  • 无菌(Sterility)

    The sterility testing was performed by membrane filtration method described in CP<1101>, USP<71> and Eur. Ph. 2.6.1.

  • 支原体(Mycoplasma)

    Negative.

  • 纯度(Purity)

    95% as determined by SDS-PAGE.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in 20 mM NaAc-HAc, pH5.0 with protectants.

    Contact us for customized product form or formulation.

  • 运输(Shipping)

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • 存储(Storage)

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

产品展示

  • 电泳(SDS-PAGE)

    Thrombopoietin SDS-PAGE

    GMP Human Thrombopoietin Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • 活性(Bioactivity)-CELL BASE

     Thrombopoietin CELL

    GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) stimulates proliferation of Mo7e cells. The specific activity of GMP Human Thrombopoietin Protein is >1.00ⅹ10^7 IU/mg, which is calibrated against human TPO Standard (NIBSC code: 03/124) (QC tested).

    Protocol
  •  Thrombopoietin CELL

    The activity of GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) was higher than other competing products.

  • 应用数据(Application Data)

     Thrombopoietin APPLICATION DATA

    GMP Human SCF Protein (Cat. No. GMP-SCFH25), GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25), GMP Human Flt-3 Ligand Protein (Cat. No. GMP-FLLH28), GMP Human FGF basic Protein (Cat. No. GMP-FGCH17) and GMP Human VEGF165 Protein (Cat. No. GMP-VE5H23) could significantly promote the iPSC differentiation to HSPCs after 14 days, highly expressed hematopoietic stem cell markers CD34 and CD45.

  •  Thrombopoietin APPLICATION DATA

    GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) is crucial for the expansion of human CD34+ hematopoietic cells cultured with medium containing GMP Human SCF Protein (Cat. No. GMP-SCFH25) and GMP Human Flt-3 Ligand Protein (Cat. No. GMP-FLLH28). Cell viability was checked using a luminescent cell viability detection reagent.

  • 稳定性(Stability)

     Thrombopoietin STABILITY

    The Cell based assay shows that GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) is stable at 37°C for 24 hours.

  •  Thrombopoietin STABILITY

    The Cell based assay shows that GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) is stable at 4°C for 180 days.

  •  Thrombopoietin STABILITY

    The Cell based assay shows that GMP Human Thrombopoietin Protein (Cat. No. GMP-THNH25) is stable after freezing and thawing 3 times.

  •  Thrombopoietin STABILITY

    The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG Thrombopoietin.

用户评价
发表评论

背景介绍

Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders (1-3). The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80‑85 kDa protein that consists of an N‑terminal domain with homology to Erythropoietin (Epo) and a C‑terminal domain that contains multiple N‑linked and O-linked glycosylation sites (4, 5). Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C‑terminal substitutions (6). Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors (4, 5, 7). Several other cytokines can promote these functions as well but only in cooperation with Tpo (8, 9). Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage (8, 9). Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10-13). It is cleaved by platelet-derived thrombin following Arg191 within the C‑terminal domain and subsequently at other sites upon extended digestion (14). Both full length Tpo and shorter forms circulate in the plasma, with the shorter, N‑terminal EPO-like domain forms showing significantly increased specific activity (4, 5, 15). The C‑terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5). Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia-sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (16, 17).

重要声明

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. Designed under ISO 9001:2015 and ISO 13485:2016, Manufactured and QC tested under a GMP compliance factory.
    2. Animal-Free materials
    3. Materials purchased from the approved suppliers by QA
    4. ISO 5 clean rooms and automatic filling equipment
    5. Qualified personnel
    6. Quality-related documents review and approve by QA
    7. Fully batch production and control records
    8. Equipment maintenance and calibration
    9. Validation of analytical procedures
    10. Stability studies conducted
    11. Comprehensive regulatory support files

    Request For Regulatory Support Files(RSF)
    Request For DMF

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Residual moisture
    11. Batch-to-batch consistency

  • DISCLAIMER

    ACROBiosystems GMP grade products are designed for research, manufacturing use or ex vivo use. CAUTION: Not intended for direct human use.

  • TERMS AND CONDITIONS

    All products are warranted to meet ACROBiosystems Inc.’s (“ACRO”) published specifications when used under normal laboratory conditions.

    ACRO DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, ACRO DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

    NOT WITH STANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN ACRO AND PURCHASER FOR THE PURCAHSE OF THE PRODUCTS, ACRO’S TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO ACRO FOR THE RELEVANT PRODUCTS. IN NO EVENT WILL ACRO BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

  • END USER TERMS OF USE OF PRODUCT

    The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

    The End User is aware that ACROBiosystems Inc. and its affiliate (“ACRO”) sell GMP grade products designed for research, manufacturing use or ex vivo use and not intended for human in vivo applications. The End User further agrees, as a condition of the sales of ACRO’s GMP grade products that: a) the End User will not use this GMP grade product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the applicable review board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

前沿进展

 
药物研发进展
  • 英文全称:

    Thrombopoietin

  • 中文全称:

    血小板生成素

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    1 详情

  • 最高研发阶段:

    临床一期

联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品详情
  • 产品展示
  • 用户评价
  • 背景介绍
  • 重要声明